News articles about PRA Health Sciences (NASDAQ:PRAH) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. PRA Health Sciences earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 46.6416234549556 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news articles that may have effected Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

A number of research firms have issued reports on PRAH. BidaskClub raised PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Zacks Investment Research raised PRA Health Sciences from a “hold” rating to a “buy” rating and set a $103.00 target price for the company in a research report on Thursday, January 11th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $104.00 target price (up previously from $101.00) on shares of PRA Health Sciences in a research report on Thursday, February 22nd. Robert W. Baird set a $94.00 target price on PRA Health Sciences and gave the stock a “buy” rating in a research report on Friday, December 1st. Finally, Mizuho set a $87.00 target price on PRA Health Sciences and gave the stock a “buy” rating in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $95.67.

Shares of PRA Health Sciences (PRAH) traded down $0.09 during midday trading on Friday, hitting $90.77. The stock had a trading volume of 388,217 shares, compared to its average volume of 450,271. PRA Health Sciences has a 52 week low of $58.08 and a 52 week high of $95.90. The company has a debt-to-equity ratio of 1.31, a current ratio of 0.90 and a quick ratio of 0.90. The stock has a market capitalization of $5,785.84, a P/E ratio of 68.77, a price-to-earnings-growth ratio of 1.42 and a beta of 0.46.

PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings results on Wednesday, February 21st. The medical research company reported $1.04 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.02 by $0.02. PRA Health Sciences had a return on equity of 22.77% and a net margin of 3.85%. The business had revenue of $568.80 million for the quarter, compared to analysts’ expectations of $543.78 million. During the same quarter in the previous year, the firm posted $0.71 earnings per share. The company’s revenue was up 37.5% compared to the same quarter last year. sell-side analysts expect that PRA Health Sciences will post 3.81 earnings per share for the current fiscal year.

In related news, VP Linda Baddour sold 67,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $90.27, for a total value of $6,048,090.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider David W. Dockhorn sold 72,850 shares of the business’s stock in a transaction dated Thursday, December 28th. The stock was sold at an average price of $90.83, for a total value of $6,616,965.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 212,700 shares of company stock worth $19,282,021. Insiders own 2.10% of the company’s stock.

WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2018/03/16/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-pra-health-sciences-prah-share-price.html.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Insider Buying and Selling by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.